Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run for its money. Illumina has long dominated the next-generation sequencing and clinical markets and another – potentially superior – high-throughput system on the horizon could put planned purchases on hold.